Lilly and Dexcom team up on new program to help improve diabetes management

Companies will partner to promote Lyumjev, Lilly's new rapid-acting insulin, with Dexcom G6 Continuous Glucose Monitoring (CGM), highlighting the benefits of using each INDIANAPOLIS and SAN DIEGO , Oct. 7, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) and DexCom, Inc.